Cited by 508Alzheimer's disease research and treatmentsBarrier Structure and Function StudiesNeurological Disease Mechanisms and Treatments

Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models

Open access
Cruz Hernández, Jean C., Bracko, Oliver, Kersbergen, Calvin J., Muse, Victorine, Haft-Javaherian, Mohammad, Berg, Maxime, Park, Laibaik, Vinarcsik, Lindsay K. +18 more·2019·Nature Neuroscience

Published version of a preprint

Abstract

Cerebral blood flow (CBF) reductions in Alzheimer's disease patients and related mouse models have been recognized for decades, but the underlying mechanisms and resulting consequences for Alzheimer's disease pathogenesis remain poorly understood. In APP/PS1 and 5xFAD mice we found that an increased number of cortical capillaries had stalled blood flow as compared to in wild-type animals, largely due to neutrophils that had adhered in capillary segments and blocked blood flow. Administration of antibodies against the neutrophil marker Ly6G reduced the number of stalled capillaries, leading to both an immediate increase in CBF and rapidly improved performance in spatial and working memory tasks. This study identified a previously uncharacterized cellular mechanism that explains the majority of the CBF reduction seen in two mouse models of Alzheimer's disease and demonstrated that improving CBF rapidly enhanced short-term memory function. Restoring cerebral perfusion by preventing neutrophil adhesion may provide a strategy for improving cognition in Alzheimer's disease patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-018-0329-4

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cruz Hernández, J. C., Bracko, O., Kersbergen, C. J., Muse, V., Haft-Javaherian, M., Berg, M., Park, L., Vinarcsik, L. K., Ivasyk, I., Rivera, D. A., Kang, Y., Cortes-Canteli, M., Peyrounette, M., Doyeux, V., Smith, A., Zhou, J., Otte, G., Beverly, J. D., Davenport, E., Davit, Y., Lin, C. P., Strickland, S., Iadecola, C., Lorthois, S., Nishimura, N., & Schaffer, C. B.
Affiliations
  • Cornell University (US)
  • Centre National de la Recherche Scientifique (FR)
  • Harvard University (US)
  • Rockefeller University (US)
Corresponding author
  • Nishimura, Nozomi
  • Schaffer, Chris B.
Venue
Nature Neuroscience
Published
2019-02-11
Volume
22
Issue
3
Pages
413-420
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2911407981
Cited by
508
References
66
Citations by year
2026: 53 · 2025: 73 · 2024: 74 · 2023: 75 · 2022: 79 · 2021: 66 · 2020: 53 · 2019: 33
FWCI
39.59
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Open Archive Toulouse Archive Ouverte (University of Toulouse) (acceptedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Science Foundation
  • Alzheimer's Drug Discovery Foundation
  • L'Oreal USA
  • Deutsche Forschungsgemeinschaft
  • National Institutes of Health (AG049952)
  • National Institute on Aging (RF1AG049952, F32AG031620, R01AG049952)
  • National Institute of Neurological Disorders and Stroke (R01NS108472, R01NS037853, R01NS097805)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, neutrophil adhesion, cerebral blood flow, APP/PS1 mice, 5xFAD mice, Ly6G, neutrophil depletion, memory impairment, spatial memory, working memory, cerebral perfusion
MeSH terms
Alzheimer Disease, Animals, Antibodies, Antigens, Ly, Brain, Capillaries, Disease Models, Animal, Female, Male, Memory, Mice, Inbred C57BL, Mice, Transgenic, Models, Neurological, Neutrophils, Peptide Fragments, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review